Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

FDA supports favorable risk-benefit profile for Luitpold's Injectafer

Feb. 7, 2008

Recent patents report new therapeutic agents for obesity and lipoprotein disorders

Feb. 7, 2008

Generex selects 72 clinical centers to participate in phase III study of Oral-lyn

Feb. 7, 2008

Statistical significance achieved in phase III studies for Puricase in gout

Feb. 7, 2008

Salsalate reduces glycemia in obese subjects

Feb. 7, 2008

Dosing completed in first cohort in formal pharmacokinetic study for Zenvia

Feb. 6, 2008

Zydus Cadila enters into collaborations with Prolong and Karo Bio

Feb. 6, 2008

New therapeutic agents for diabetes described in recent patents

Feb. 6, 2008

Genzyme and Isis granted Hart-Scott-Rodino clearance for collaboration agreeement

Feb. 5, 2008

Glenmark to get back global rights to melogliptin from Merck Serono

Feb. 5, 2008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...
Biogen AD drug shows tau, cognition benefit, despite trial miss
BioWorld
Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...